| pubmed-article:10517211 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C1522565 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C0021308 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C0028116 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C0428772 | lld:lifeskim |
| pubmed-article:10517211 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10517211 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10517211 | pubmed:dateCreated | 1999-11-4 | lld:pubmed |
| pubmed-article:10517211 | pubmed:abstractText | Left ventricular (LV) remodelling following acute myocardial infarction has generally been studied in patients with LV ejection fraction (EF) < 40%, and it has been shown that this process can be attenuated by ACE inhibitors. Little is known regarding LV remodelling in patients with LVEF > or = 40% or the effects of treatment in this patient cohort. The DEFIANT II study (Doppler Flow and Echocardiography in Functional cardiac insufficiency) included 542 post-infarction patients with LVEF 25-50% without overt heart failure within 13 days following acute myocardial infarction (AMI). They were then randomized to nisoldipine coat-core (CC) or placebo and followed up for 6 months. | lld:pubmed |
| pubmed-article:10517211 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10517211 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517211 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10517211 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517211 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517211 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10517211 | pubmed:issn | 1401-7431 | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:OtterstadJ... | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:St John... | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:ParkerAA | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:PlappertTT | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:KirwanBB | lld:pubmed |
| pubmed-article:10517211 | pubmed:author | pubmed-author:LubsenKK | lld:pubmed |
| pubmed-article:10517211 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10517211 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:10517211 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10517211 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10517211 | pubmed:pagination | 234-41 | lld:pubmed |
| pubmed-article:10517211 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:meshHeading | pubmed-meshheading:10517211... | lld:pubmed |
| pubmed-article:10517211 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10517211 | pubmed:articleTitle | Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study. | lld:pubmed |
| pubmed-article:10517211 | pubmed:affiliation | Division of Cardiology, Vestfold Central Hospital, Tønsberg, Norway. | lld:pubmed |
| pubmed-article:10517211 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10517211 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10517211 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10517211 | pubmed:publicationType | Multicenter Study | lld:pubmed |
